Blonanserin - Sumitomo Dainippon Pharma

Drug Profile

Blonanserin - Sumitomo Dainippon Pharma

Alternative Names: AD-5423; DSP-5423; DSP-5423P; Lonasen

Latest Information Update: 18 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Bukwang Pharmaceutical; Dainippon Sumitomo Pharma; Nitto Denko; Sumitomo Dainippon Pharma
  • Class Antipsychotics; Piperazines; Piperidines
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia

Most Recent Events

  • 10 Sep 2018 Efficacy and adverse events data from a phase III trial for Schizophrenia (in adults) (Transdermal) released by Sumimoto Dainippon Pharma
  • 31 Jul 2018 Preregistration for Schizophrenia (In adults) in Japan (Transdermal)
  • 19 Feb 2018 Efficacy and adverse events data from a phase III trial of transdermal blonanserin in Schizophrenia released by Sumitomo Dainippon Pharma and Nitto
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top